CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Clinical Trials
Original article

The $10B TAVR Market Grew. Why Are Most Patients Still Untreated?

DurAVR THVPositive
AI Analysis

Summary

Anteris is introducing DurAVR THV, a transcatheter aortic valve replacement device designed with a pharma-style disease-management approach to address the TAVR market's treatment gap.

Importance:3/10
Sentiment:
0.30
TAVRMedical DevicesValve ReplacementMarket Commentary

Read the original article

Published by PR Newswire Clinical Trials on July 13, 2026 12:04 PM

Read Original